TrialBlood cancer journal2016

Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.

S J Jacobus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.